Jaguar Health Inc's subsidiary Napo Pharmaceuticals has signed an $18 million licensing agreement with Woodward Specialty, granting exclusive rights to commercialize Mytesi and Canalevia in the U.S.
The deal includes an upfront payment of $18 million, with $16 million at signing and $2 million contingent on specific conditions. Additionally, Napo could earn up to $17 million in milestone payments as targets are met, which could significantly enhance future revenue growth. This agreement also features a buyback option for Napo to reacquire rights after five years, contingent on FDA approval for new Mytesi indications.
Despite the stock's 92.87% surge to $1.47 following the announcement, it has faced a 95.02% decline over the past year, indicating ongoing long-term challenges that may affect the sustainability of short-term gains.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
